Cardiovascular effects of a novel antihypertensive agent, SGB-1534, in miniature pigs.
The cardiovascular effects of SGB-1534 (3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]-2,4(1H,3H)-quinazolinedione monohydrochloride) were investigated in pentobarbital-anesthetized miniature pigs. SGB-1534 infused i.v. at a rate of 3 micrograms/kg . hr-1 caused a gradual decrease of systemic blood pressure reaching a plateau level, with a peak fall of about 20% of the preinfusion value, 30-60 min after the start of the infusion. Significant reductions of coronary vascular resistance and left ventricular (LV) end-diastolic pressure were also observed. Changes in LV systolic pressure, coronary blood flow and pressure-rate product were not significant, while heart rate and LVdp/dt max were significantly increased. The pressor response to a bolus i.v. injection of epinephrine (1 microgram/kg) was significantly inhibited during i.v. infusion of SGB-1534. The results indicate that SGB-1534 is an antihypertensive agent, probably related to its alpha-adrenergic blocking action in peripheral vasculatures.
D000758:Anesthesia; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D008297:Male; D011799:Quinazolines / Q000494:pharmacology*; D013552:Swine; D013556:Swine, Miniature; D013997:Time Factors
D000959:Antihypertensive Agents; D011799:Quinazolines; C042712:SGB 1534; D004837:Epinephrine